• 
  Mission

  
  
  

  At Upaya Pharmaceuticals, LLC our mission is to develop and commercialize new drugs that revitalize existing antibiotics for the treatment of antibiotic resistant infections. Our competitive SynAmp Technology™ provides a new platform for drug discovery and development. Motivated to provide better therapeutic solutions to patients, our team is impelled to develop a portfolio of pre-clinical and clinical combination antibiotics to solve this critical healthcare challenge caused by resistant bacteria.

  • 
    

The Upaya Solution.

“Bacteria resistant to antibiotics caused 2 million illnesses
and 23,000 deaths in the United States alone.” CDC, 2013

Our new class of drugs has shown the ability to inhibit
the activity of efflux pumps in the antibiotic-resistant
Gram-negative bacteria. The combination of the existing antibiotics with our drug candidates enhance the antibiotic’s potency by up to 30-fold – even though the bacterium is resistant to that antibiotic. Our drug candidate will provide a non-oral treatment for patients in hospitals that are suffering from life threatening infections. Our
pre-clinical pipeline covers a broad range of therapeutic applications including hospital acquired pneumonia, urinary tract infections, tuberculosis, etc.

Upaya Pharmaceuticals is developing a new technology that:
• Significantly increases antibiotic potency, and
• Recovers antibiotic activity in resistant bacteria

• Mohit B. Patel, M.Sc. (Director of Business Development). Mr. Patel received a M.S. degree in Biochemistry & Biotechnology in 2012. During this time he co-founded a biotechnology startup company focused on commercializing a gene delivery technology. Here he gained a yearlong experience in performing market research, developing a business model, team development and fundraising. He is familiar at identifying key medical needs and developing a technology/startup company to address it. Mr. Patel is currently a Ph.D. candidate in Cell and Molecular Biology at University of Missouri-St. Louis. His research expertise includes microbiology, biochemistry and antibiotic resistance. He has developed numerous biomedical and agricultural applications for novel synthetic molecules, has co-authored 7 publications and 3 patent applications, including co-inventing Upaya’s basic technology.
  
  Michael R. Gokel, B.S.E.E. (Director of Operations). received the B.S. degree in electrical engineering with a minor in mathematics and equivalent minors in computer engineering and chemistry. After University, he considered pursuing an advanced degree in Chemistry but decided to gain non-academic experience as a general manager of a Jimmy Johns franchise in Columbia, Missouri. His actual business experience organizing a workforce, maintaining stock, handling logistics, and managing income and revenue records brings important practical experience to the team. He doubles as a chemical biologist and has been intimately involved with antimicrobial studies as well as handling operations and records.
•